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Abstract 
On the basis of the antiviral properties exhibited by the natural green tea catechins that contain galloyl groups, we here 
describe the synthesis of novel synthetic analogues that contain in a single molecule two, three or five units of galloyl 
(3,4,5-trihydroxybenzoyl) or its isomer 2,3,4-trihydroxybenzoyl, as well as other mono- or dihydroxybenzoyl moieties. 
These molecules have been evaluated for their in vitro inhibitory effects against a wide panel of viruses showing 
preferential activity against HIV and HCV.  
Our structure-activity relationship studies demonstrated that the 2,3,4-trihydroxybenzoyl moiety provides better 
antiviral activities than the galloyl (3,4,5-trihydroxybenzoyl) moiety that is present in natural green tea catechins. This 
observation can be of interest for the further rational exploration of compounds with anti-HCV/HIV properties.  
The most notable finding with respect to HIV is that the tripodal compounds 43 and 45, with three 2,3,4-
trihydroxybenzoyl moieties, showed higher activities than linear compounds with only one or two. With respect to HCV, 
the linear compounds, 52 and 41, containing a 12 polymethylene chain and two 2,3 di- or 2,3,4 tri-hydroxybenzoyl groups 
respectively at the ends of the molecule showed good antiviral efficiency. Furthermore, the anti-HCV activity of both 
compounds was observed at concentrations well below the cytotoxicity threshold. A representative member of these 
compounds, 41, showed that the anti-HCV activity was largely independent of the genetic make-up of the HCV 
subgenomic replicon and cell lines used.  
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1. Introduction 
Several chronic viral infections (such as AIDS and hepatitis C) are highly prevalent and a serious health risk for 
which there is no curative treatment and no vaccine.  
Hepatitis C virus (HCV) belongs to the family of Flaviviridae and is an important aetiological agent causing chronic 
hepatitis that can progress further to hepatocellular carcinoma [1]. A “dual therapy” based in the combination of pegylated 
interferon-alpha (PEG-IFNα) and ribavirin was the standard therapy of chronic HCV infection for more than 10 years [2]. 
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In recent years the advances in the knowledge of the hepatitis C life cycle resulted in the development of different classes 
of direct-acting antiviral (DAA) agents [3]. These drugs act as inhibitors of different non-structural HCV proteins such as: 
NS3/4A protease, NS5BRNA-dependent RNA polymerase and NS5A. In 2011, the first two DDAAs, telaprevir and 
boceprevir, targeting the NS3/4A protease of HCV, have been approved by the FDA for chronic HCV infection [4]. These 
drugs, used in combination with peginterferon and ribavirin as a “triple therapy”, have significantly increased the 
sustained viral response rate for patients infected with genotype 1 viruses (~ 75% versus ~ 45%, in the “dual” combination 
therapy). Despite this major therapeutic success the “triple therapy” is associated with numerous side effects and is limited 
to genotype 1 viruses [5]. These limitations highlighted the urgent need for new lead compounds and novel therapeutic 
concepts to fight against Hepatitis C infection. 
With respect to infection with Human Immunodeficiency virus (HIV), the introduction of highly active antiretroviral 
therapy (HAART), in the late 1990s, have significantly contribute to reduce the morbidity and mortality due to infection 
with this virus [4]. However, issues such as long-term toxicities, drug-drug interactions and emergence and transmission 
of drug-resistant viral strains represent  a serious problem to long-term successful treatment that justify the search for new 
therapeutic approaches and drugs for the treatment of this infection [6]. 
Polyphenols or vegetable tannins are a diverse group of natural compounds characterized by the presence of multiple 
phenolic functionalities per molecule [7]. They are secondary metabolites produced by higher plants as a defense strategy 
against invading pathogens including insects, bacteria, fungi and viruses or as a response to environmental stress [8]. In 
addition, polyphenols serve to dissuade herbivores from eating plants due to their unpleasant and anti-nutritional 
properties [9].  
Green tea (Camellia sinensis), one of the most popular beverages in the world, is an important source of polyphenols, 
especially flavonoids of the catechin-type. Among them, (-) epigallocatechin gallate (EGCG) is the most abundant (40-
60%), followed by (-) epicatechin gallate (ECG, 10-20%), (-) epigallocatechin (EGC, 10-20%) and (-) epicatechin (EC, 4-
6%) [10].  
The green tea catechins are well-known for their antioxidant properties [11] and their beneficial therapeutic effects 
against some forms of cancer [12] cardiovascular [13] and neurological diseases [14]. In addition many antimicrobial 
activities [15], such as antibacterial [16], antifungal [17] and antiviral [18] have been described for this group of 
molecules..  
Nowadays it is generally accepted that the pyrogallol and galloyl groups, present in several natural tea catechins, are 
responsible for most of their antioxidant, anticancer and antimicrobial activities [19,20]. In fact, EGCG and ECG, having a 
3-galloyl side-chain, showed higher antimicrobial activity and anticancer properties than catechins, like EC and EGC, that 
lack the galloyl moiety.  
In the light of the wide range of biological activities attributed to natural green tea catechins they have been used as 
lead structures for the development of synthetic analogues. Among them, n-alkyl esters of gallic acid, also known as alkyl 
gallates, have become a focus of attention because of their antioxidant properties. In fact, they have been widely employed 
as antioxidant additives in both, food and pharmaceutical industry [21]. In addition, there are numerous studies 
demonstrating that alkyl gallates have a wide range of biological activities including anticancer [22], antibacterial [23], 
antifungal [24] and antiviral activity [25].  
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Taking into account that the pyrogalloyl and galloyl groups present in natural tea catechins and synthetic alkyl 
gallates are responsible for most of their biological activities we considered of particular interest the combination of two or 
more of these galloyl moieties, or other related phenolic substituents, in a single molecule as a novel class of synthetic 
alkyl gallates. We reasoned that this approach would allow obtaining molecules with enhanced biological activity with 
respect to the “classical” alkyl gallates (with only one galloyl residue per molecule). Here we report the synthesis of 
binary, tri- and penta- alkyl gallate analogues and their antiviral effects against a wide variety of viruses. 
In these compounds gallic acid (3,4,5-trihydroxybenzoic acid) and its isomer 2,3,4-trihydroxybenzoic acid, together 
with other mono- and dihydroxybenzoyl residues have been used as phenolic substituents while linear or branched 
polyamines or polyalcohols of different lengths and architectures were used as scaffolds. These scaffolds allowed the 
introduction, on the same molecule of a variable number of phenolic residues (from two to five) and the modification of 
the distance and spatial distribution between them (Figure 1).  
 
 
Fig. 1. Target linear and branched polyphenols 
 
To determine the impact of the chemical structure on the antiviral activity we studied: i) the nature of the linkage 
between the gallic acid residues and the hydrocarbon chain (ester or amide); ii) the number of galloyl units bound to a 
given scaffold; iii) the number and position of OH groups on the aromatic ring.  
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2. Results and discussion 
2.1. Chemical results   
Firstly, several members of the well-known n-alkyl esters of gallic acid (alkyl gallates) (2-7) have been synthesized in 
our laboratory (Scheme 1) in order to be used as reference compounds in the biological evaluation. In our hands 
microwave conditions [26] prove superior than other more classical conditions [25d, 27]. Briefly, gallic acid 1 with the 
appropriate alcohol and trace amounts of concentrated sulfuric acid as catalyst were microwave-irradiated during 50 min 
at 100 ºC to give gallates 2-7 with excellent yields (82%-98%).  Compared with the classical synthetic route, microwave 
conditions significantly reduced the reaction time (50 min at 100 ºC versus 2-12 h at 160 ºC), increase the yields (58%-
80% versus 82%-98%) and simplify the experimental protocol (use of Dean Stark or vacuum).  
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Scheme 1. Synthesis of alkyl gallates 2-7 under microwave–irradiated conditions. Reagents and conditions: (i) MW, H2SO4 
(cat.), 100 ºC, 50 min  
 
With the aim to evaluate the relationship between the number of polyphenol moieties per molecule and the antiviral 
properties, a variable number (2, 3 and 5) of polyphenol residues were attached to different central scaffolds. 
First, we prepared compounds 8-11 with two gallic acid residues at the terminal ends of the molecule (Scheme 2). To 
evaluate the influence of the length of the alkyl chain on the antiviral activity, different chain lengths were used to connect 
the two polyphenol subunits. It should be mentioned that the synthesis of some of these compounds has been previously 
described [22a, 22b, 28], however their antiviral activities were completely unknown. In the reported synthetic procedure a 
six-step route, involving protection of the phenolic functionalities, has been used. In our case a direct and shorter synthetic 
route involving only one-step reaction and non-protected phenol functionalities was attempted. Thus, in this route two 
equivalents of gallic acid was treated with the corresponding diols (1,4-butanodiol, 1,6-hexanodiol, 1,8-octanodiol and 
1,12-dodecanodiol) in the presence of a catalytic amount of  p-toluene sulfonic acid. The mixture was heated under reflux 
(160 ºC) resulting in compounds 8-11 with 28%-70% yields. Microwave-assisted conditions was also attempted for the 
synthesis of these compounds, however complex mixtures of compounds were obtained. 
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Scheme 2. Synthesis of alkyl digallates 8-11. Reagents and conditions: (i) p-TSA (cat.), dioxane, 160 ºC, 50 min  
 
Next, alkyl gallamides 18-22, containing  amide bonds instead of ester bonds and various lengths of the alkyl chain, 
were also prepared. As described in Scheme 3, these compounds were synthesized by condensation of the commercially 
available OMe-protected gallic acid chloride 12 with the corresponding diamines (1,4-butanodiamine, 1,6-hexanodiamine, 
1,8-octanodiamine, 1,10-decanodiamine and 1,12-dodecanodiamine). Reactions were performed in the presence of 
potassium carbonate using a biphasic system of ethyl acetate/water. This reaction allowed the synthesis of the OMe-
protected derivatives 13-17 in excellent yields (77%-98%). Deprotection of the methyl ether derivatives using the Lewis 
acid boron tribromide gave the deprotected final compounds 18-22 in moderate to good yields (51-84%).  
 
 
 
Scheme 3. Synthesis of alkyl digallamides18-22. Reagents and conditions: (i) K2CO3, AcOEt/H2O (1:1) (ii) BBr3, CH2Cl2  
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The same synthetic methodology was applied for the synthesis of the OMe protected trigalloyl (23, 25 and 27) 
(Scheme 4) and pentagalloyl 29 (Scheme 5) derivatives that were obtained in 38%-85% yields. In this case, 
diethylenetriamine, spermidine, tris(2-aminomethyl)amine and tetraethylenepentamine were used as starting amines. 
Deprotection of the methyl ether derivatives 23, 25, 27 and 29 using the Lewis acid boron tribromide gave the 
corresponding deprotected final compounds 24, 26, 28 [29] and 30 in moderate to good yields (30-100%).  
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Scheme 4. Synthesis of branched trigallamides 24, 26 and 28. Reagents and conditions: (i) K2CO3, AcOEt/H2O (1:1) (ii) 
BBr3, CH2Cl2  
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Scheme 5. Synthesis of pentagallamide 30. Reagents and conditions: (i) K2CO3, AcOEt/H2O (1:1) (ii) BBr3, CH2Cl2  
 
 
In order to investigate the effect of the spatial distribution of the hydroxyl groups on the aromatic ring, the 
corresponding 2,3,4-trihydroxybenzoyl isomeric derivatives 32-45 (Scheme 6) were also synthesized. In this case, the 
2,3,4-benzyl protected intermediate 31 was employed as starting compound (Scheme 6). In turn, intermediate 31 was 
prepared starting from commercially available 2,3,4-trihydroxycarboxylic acid by perbenzylation of the carboxylic acid 
and hydroxyl groups followed by saponification of the ester group [30]. Next, condensation of 31 with the corresponding 
alkyl amine in the presence of pyBOP and triethylamine, followed by deprotection of the benzyl ether derivatives using 
H2/Pd-C gave the deprotected final compounds 37-41, 43 and 45 in moderate to good yields (35-61%). Synthesis of 
compound 45 was described in the literature [29c] using a 2-mercaptothiazoline 2,3,4-trimethoxy benzoic acid derivative, 
instead of the benzyl protected intermediate 31 used by us.  
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Scheme 6. Synthesis of 2,3,4-trihydroxybenzoyl derivatives 32-45 Reagents and conditions: (i) pyBOP, Et3N (ii) H2, Pd/C 
 
Next, to determine the impact of the number of hydroxyl groups present on the aromatic ring on the antiviral activity 
compounds 50-52 and 57-59, with two or one hydroxyl groups, respectively were prepared (Schemes 7 and 8).  
The dihydroxy-benzoyl analogues 50-52 (Scheme 7) were previously synthesized by different authors [31] although 
their antiviral properties were completely unknown. In our case a modification of the previously described procedures, that 
implies the use of pyBOP as coupling reagent, has been used for the synthesis of these compounds. In this reaction, the 
commercially available 2,3-dimethoxybenzoic acid 46 (Scheme 7) was used as starting material.  Reaction of this 
intermediate with ethylene, tetramethylene and dodecamethylene diamines in the presence of pyBOP and triethylamine, 
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followed by deprotection of the methyl ether derivatives 47-49 using the Lewis acid boron tribromide gave the deprotected 
final compounds 50-52 with excellent yields (81-99%).  
 
 
 
Scheme 7. Synthesis of 2,3-dihydroxybenzoyl derivatives 50-52. Reagents and conditions: (i) pyBOP, Et3N (ii) BBr3, 
CH2Cl2 
 
The coupling reagent, pyBOP, was also used for the synthesis of the monohydroxy benzoyl analogues 57-59 (Scheme 
8). In this case the commercially available 2-benzyloxy salicylic acid 53 was used as starting material. Reaction of this 
intermediate with the corresponding alkyl amine in the presence of pyBOP, as coupling reagent, and triethylamine 
followed by deprotection of the benzyl ether derivatives 54-56, using H2/Pd-C, gave the deprotected final compounds 57-
59 with good to excellent yields (69-92%).  
 
 
 
Scheme 8. Synthesis of  2-monohydroxybenzoyl derivatives 57-59. Reagents and conditions: (i) pyBOP, Et3N (ii) H2, Pd/C  
 
As it will be later discussed in the Antiviral Evaluation section, alkylgallamide 41 (Scheme 6), containing a twelve 
methylene linker connecting two phenolic subunits at the ends, showed significant anti-HCV activity in cell culture. To 
complete the structure-activity relationship studies of this compound we prepared compounds 61, with a less lipophilic 
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linker, and 63 with the phenolic OHs protected as OMe (Scheme 9). The synthesis of these compounds were accomplished 
by coupling of intermediates 31 and 62 with the corresponding amines in the presence of pyBOP ant triethylamine.  
 
 
Scheme 9. Synthesis of  derivatives 61 and 63. Reagents and conditions: (i) pyBOP, Et3N (ii) H2, Pd/C 
2.2 Biological results  
Firstly, the new synthetic phenolic derivatives have been evaluated for their in vitro inhibitory effects against a wide 
panel of viruses such as: vaccinia, vesicular stomatitis, Coxsackie B4, respiratory syncytial, para-influenza-3, reovirus, 
Sindbis, influenza A (H1N1, H3N2), Punta Toro, feline corona, feline herpes and Chikungunya. None of these compounds 
showed activity against these viruses.  
Next, the new synthetic compounds were evaluated against HIV. Gallic acid (1), the commercially available natural 
polyphenols (EGCG, ECG, EGC and EC) and the “classical” alkyl gallates 2-7 were also included for comparative 
purpose. Compounds xxx and xxxx were also included as positive controls respectively.  
None of the OMe- or OBn-protected compounds proved active at subtoxic concentrations (data not shown). These 
data point to the importance of unsubstituted phenolic OHs for activity.  
Table 1 summarizes the results of the anti-HIV evaluation of the deprotected compounds. 
 
Table 1. Inhibitory effect of test compounds against HIV-1 and HIV-2 in CEM cell cultures  
 
                      EC50 (µM)a 
CC50 (µM)b 
 HIV-1 (IIIB)  HIV-2 (ROD) 
1  >50 >50 >250 
EGCG >10 >10 -- 
ECG >50 >50 104 ± 12.3 
EGC >50 >50 -- 
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EC >250 >250 >250 
2  >10 >10 23 ± 0 
3  >10 >10 55 ± 43 
4  14 ± 5 ≥10 47 ± 38 
5 5.4 ± 0.6 6.6 ± 1.1 14 ± 3 
6  >2 >2 11 ± 8 
7  ≥ 1 ≥ 1 2.8 ± 0.4 
8  >10 >10 21 ± 3 
9  ≥ 10 ≥ 10 22 ± 0.4 
10 >10 >10 13 ± 7 
11  4.6 ± 0.1 > 10 4.7 ± 0.3 
18 5.2 ± 0.9 > 10 23 ± 1 
19  > 10 > 10 72 ± 39 
20  > 10 _ 51 ± 28 
21  >50 >50 86 ± 12 
22  19 ± 12 26 ± 2.1 58 ± 7.8 
24  > 10 > 10 34 ± 14 
26  18 ± 16 -- 107 ± 0.7 
28  10 ± 0.0 -- 54 ± 33 
30 4.9 ± 0.6 > 10 21 ± 1.4 
37 >10 >10 109 ± 87 
38  >50 >50 102 ± 4.2 
39  >50 >50 82 ± 11 
40  >50 >50 100 ± 4.9 
41 >10 >10 55 ± 21 
43 2.6 ± 2.3 >10 27 ± 0.7 
45 2.5 ± 1.9 >10 28 ± 9.3 
50 >10 >10 19 ± 5.5 
51 > 2 -- 5.2 ± 0.8 
52 > 2 > 2 4.8 
57 >10 >10 25 ± 2.8 
58 > 10 -- 35 ± 3.5 
59 > 250 > 250 248 
61 >50 >50 81 ± 11 
    
Xxxxxx(positive 
control) 
   
 
a 50% Effective concentration, or compound concentration required to inhibit HIV-induced cytopathicity by 50%. 
b 50% Cytostatic concentration, or compound concentration required to inhibit cell proliferation (CEM) by  50%. 
Data are the mean ±S.D. of at least 2 to 3 independent experiments 
 
As it was shown in Table 1 gallic acid (1) did not show any anti-HIV activity up to 50 µM. Also the natural 
polyphenols of the catechin-type EGCG, ECG, EGC and EC were inactive at subtoxic concentrations. 
Within the group of alkyl gallates, compounds 2 to 7, only pentyl and hexyl gallates (4 and 5) were endowed with 
anti-HIV-1 and -HIV-2 activity below, but close to subtoxic concentrations. Although their activity is close to the toxicity 
threshold (antiviral selectivity index ∼ 2 to 4) these data are important because they represent a first hint of activity in this 
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compound series. Moreover, and taking into consideration that gallic acid as such did not exhibit any antiviral activity 
against HIV, this result indicates that the alkyl moiety plays an important role in the eventual antiviral activity. 
The digallates 8 to 11 could not improve the activities obtained for the monoesters.  
Within the group of alkyl digallamides (18 to 22), the most active compound was 18, with a spacer of 4 methylenes, 
followed by 22 with a chain of 12 methylenes, as spacer. Again, the antiviral selectivity index was around 3 to 4, as 
observed for the alkyl gallates. 
Within the group of compounds with 3 (24, 26, 28) or 5 (30) units of gallic acid, the most active agent was 30 (EC50 
HIV-1: 4.9 µM; selectivity index ∼ 4). The spermidine derivative 26 showed an EC50 of 18 µM, but proved the least toxic 
compound in this series (CC50: 107 µM), resulting in a selectivity index of ∼ 6. 
The alkyl amides 37 to 41 with only two phenolic rings were inactive at subtoxic concentrations. Interestingly, 
branched compounds 43 and 45 bearing 3 phenolic rings with hydroxyl groups at positions 2,3,4 were endowed with the 
most pronounced anti-HIV activity among all compounds evaluated (EC50: 2.5-2.6 µM). Activity showed by these 
compounds are below the toxicity threshold (CC50: 27-28 µM)), resulting in selectivity indexes of ∼ 10).  
The compounds 50-52 and 57-59 in which gallic acid has been replaced by aromatic rings with only 2 or 1 hydroxyl 
groups, respectively, were inactive. 
Importantly, the spermidine derivative 26, substituted with 3 gallic acid moieties was less active than compound 43 
substituted with three 2,3,4-trihydroxyphenyl rings. Similarly, compound 28 containing a tris(2-aminoethyl)amine 
skeleton substituted with 3 gallic acid moieties proved less active than 45 with the same skeleton and three 2,3,4-
trihydroxy phenyl rings showing that the 2,3,4-trihydroxyphenyl moiety provides better anti-HIV activities than the gallic 
acid moiety.  
Next, the new synthetic polyphenols were also evaluated for their in vitro inhibitory effects on hepatitis C virus 
replication. Table 2 summarizes the results of the anti-hepatitis C virus evaluation of the test compounds. The HCV NS3 
protease inhibitor (Telaprevir) was included as positive control. 
 
 
Table 2. Antiviral effect of the test compounds on hepatitis C virus replication in the Huh 5-2 replicon system  
 
    Compound EC50 (µM)a,d EC90 (µM)b,d CC50 (µM)c,d    
2  19  >45  45  
3  13  >29 29  
4 14  >50 >50                 
5  9.0  >50 >50                 
7  0.4  1.8  8.9  
8  39  >50 >50                  
9  16  --- >50                  
10 17  55  80  
11  6.5  37  >50                  
18  18  >29  29  
19 11  >24 24  
20  23  >50 >50                  
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21  20  --- 47  
22  27  >100 >100                   
28  > 2.9 > 2.9 > 2.9                 
30  34  > 50 >50                   
37 15  >50 >50                    
38  14  --- 32  
39  25  --- 34  
40  11  --- >100              
41  2.5  6.1  >100              
43  34  >50 >50                  
45  >5.5  >5.5  >3.7  
52  2.0  4.8  108  
58  11  --- >49                  
59  4.7  >6.7 >6.7                     
61  28  --- 49   
63  >3.5 --- 5.4  
Telaprevir (VX-950) 2.8 --- 47 
 
 
a EC50 = 50% effective concentration (concentration at which 50% inhibition of virus replication is observed). 
b EC90 = 90% effective concentration (concentration at which 90% inhibition of virus replication is observed). 
c CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host 
cell).  
. 
 
 
As it was shown for HIV none of the OMe- or OBn-protected compounds proved active at subtoxic concentrations 
(data not shown). These data point again to the importance of unsubstituted phenolic OHs as a requisite for antiviral 
activity. Table 2 summarizes the results of the anti-hepatitis C virus evaluation of the unprotected compounds. 
The “classical” alkyl gallate derivatives (2-5) showed activity against hepatitis C virus, albeit at concentrations that 
were close to the cytotoxic concentrations for the cells. Interestingly alkyl gallate 7, with a 12 methylene linker, showed an 
activity (EC50 =  0.4 µM) far beneath the toxicity threshold (CC50 >8.9), resulting in a selectivity index of >22. 
With respect to the alkyl digallates 8-11 a tendency for the best efficiency is observed for compounds with longer 
alkyl chains. For instance, an increase in activity is observed when the alkyl length is expanded from C4 (8) to C12 (11). 
The most active compound (11) has the highest anti-HCV selectivity (> 7). 
Among the alkyl amides of gallic acid 18-22 a relationship between the anti-hepatitis C virus activity and the number 
of carbons of the alkyl chain could not be found. Instead, a correlation between the lenght of the alkyl moiety and the anti-
HCV activity was found for the amide derivatives 37-41, containing two 2,3,4-trihydroxy benzoyl moieties at the two ends 
of the molecule, and 52 with two 2,3 -dihydroxy benzoyl moieties.  Among these compounds, the best antiviral efficiency 
was observed for compounds 41 and 52 containing a C12 polymethylene linker. Compound 52 (EC50 = 2.0 µM; CC50 = 
108) with two contiguous  hydroxyl groups on the aromatic ring is the most selective of this series (selectivity index: 54). 
Compound 41, with three consecutive hydroxyl groups in the 2,3,4 position on the aromatic ring, also showed an activity 
(EC50 = 2.5 µM) far beneath the toxicity threshold (CC50 >100), resulting in a selectivity index of >40. The comparable 
potency of both compounds indicates that the “extra” hydroxyl group present in 41 is not crucial for the activity. 
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Two related analogues of 41, compounds 61 and 63, have been prepared to assess the influence of the lipophilicity of 
the linking alkyl chain and the OH groups on the anti-HCV activity. The polyethylene glycol derivative 61 with a less 
lipophilic linker, was markedly less active than compound 41, with a 12 methylene linker. No anti-HCV activity was 
observed with compound 63 with the phenolic OHs protected as OMe. This result clearly demonstrates that the free OH 
groups – alike HIV - play an important role in the anti-HCV activity and might also contribute to reduce cell toxicity. 
Interestingly, alkyldigallamide 22 was less active than compound 41 revealing that the 2,3,4-trihydroxy phenyl 
moiety provides a better antiviral activity than the gallic acid moiety. These findings are consistent with previous 
observations made for HIV. 
Compound 59, containing a C12 polymethylene linker and only one single OH group on the terminal aromatic rings 
was only active at toxic concentrations. The inactivity of 59 (with only 1 OH on the aromatic ring) is in clear contrast with 
the activity shown by 41 and 52 (with 2 and 3 OHs on the aromatic ring) revealing that the presence of at least 2 hydroxyl 
groups in a contiguous position on the aromatic ring is important for antiviral activity/selectivity. 
Branched compounds 28, 43 and 45 with 3 galloyl or 2,3,4-trihydroxybenzoyl groups do not improve the antiviral 
efficacy of the linear compounds of equivalent length (19, 20, 38 and 39) with only two galloyl or 2,3,4-trihydroxybenzoyl 
groups, showing that the antiviral efficacy was not increased by the introduction of an extra (third) polyphenolic moiety. 
The same was observed for compound 30 bearing 5 galloyl groups, with respect to 21 and 22 of equivalent size. 
In summary, with respect to the anti-hepatitis C virus activity, our structure-activity relationship studies clearly show 
that the activity seems to be related with the lipophilicity and hydroxyl substitution pattern. The most noticeable finding 
was the anti-hepatitis C virus activity shown by compounds 41 and 52 containing a 12 polymethylene chain and two 2,3 
di- or 2,3,4 tri-hydroxybenzoyl groups located at the ends of the molecule, and leading to agents with a pronounced anti-
HCV activity and selectivity. The “classical” alkyl gallate 7 also shows significant activity (six and five-fold higher than 
those of 41 and 52 respectively) but its notorious toxicity makes it less attractive as lead compound.  
Compounds tested can inadvertently inhibit heterologous elements such as the encephalomyocarditis virus (EMCV) 
internal ribosome-entry site (IRES) or the neomycin phosphotransferase (neo) that are required for the proper translation 
of the HCV polyprotein in the assay system or to keep the HCV subgenomic replicon persistently in cells, respectively. 
Therefore we evaluated a representative member of the compounds reported in this study, namely 41, in different replicon 
systems. On the one hand we used Huh 9-13 HCV replicons that have the same genetic make-up as Huh 5-2 replicons, but 
differ in their composition of cell culture adaptive mutations, the absence of a luciferase reporter gene and the higher HCV 
RNA content as compared to Huh 5-2 cells [32]. Furthermore, we included a subgenomic replicon contained in HuH6 
cells that again have a similar genetic make-up as Huh 5-2 replicons, but (i) replicate in a different cell line (HuH6 cells 
instead of Huh-7 cells) and (ii) carry different adaptive mutations. Moreover, in HCV subgenomic replicon containing 
HuH6 cells, replicon replication is not inhibited by IFN-γ and viral RNA replication is independent from cell proliferation 
[33]. 
 Compound 41 proved to be active in both Huh 9-13 and HuH6 HCV subgenomic replicon containing cells at EC50-
values of 8.4 ± 1.6 µM and 33 µM, respectively, as determined by RT-qPCR. In both replicon containing cells 41 did not 
show any effect on the proliferation and metabolism of the host cell as determined by the MTS assay (CC50 >100 µM) at 
the concentrations tested. The obtained values are in the same range as for the Huh 5-2 HCV subgenomic replicon 
containing cells. These findings exclude an inhibitory effect on the luciferase expressed by the HCV subgenomic replicons 
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in Huh 5-2 cells and also show that inhibition is independent of the genetic make-up of the replicon and of the cell line 
used. 
As reported previously HCV subgenomic replicon replication is highly dependent on cell proliferation [33]. Hence, 
any compound that can induce a cytostatic effect on cell growth could result indirectly in inhibition of HCV subgenomic 
replicon replication [34]. At the concentrations tested none of the compounds showed marked inhibition of cell growth, as 
apparent from the MTS assay (see Table 2). However, microscopic examination did highlight reduced cell numbers and 
altered cell morphology for most of the phenolic derivatives tested (as exemplified in Figure 2 for 41).  
Furthermore HCV replication is highly dependent on the cellular lipid metabolism [35]. Any perturbation of the lipid 
metabolism, for example inhibition of fatty acid oxidation, might result indirectly in the inhibition of HCV replication 
[36]. Candidate drugs can perturb the lipid metabolism of a cell in different ways, for example by inducing 
phospholipidosis and steatosis, as reviewed in [37]. To assess if the compounds studied altered the cellular lipid 
metabolism we used Nile Red staining to assess the ability of compound 41 to induce phospholipidosis or drug induced 
steatosis.  
Cells treated with a serial dilutions of compound 41 were analyzed using Nile red staining to visualize the 
intracellular accumulation of neutral lipids (hallmark of phospholipidosis) and charged lipids. Overall Nile Red staining 
showed that derivative 41 significantly reduced cell growth at concentrations between 33-100 µM. Furthermore these 
treated cells show a higher charged lipid content, as apparent of the increased cytoplasmic red stain, and an apparent 
rounded cell shape (Figure 2, panels A, B) as compared to the mock-treated cells (Figure 2, panel F). At lower 
concentrations (in the same range as the EC50 and EC90-values) derivative 41 did not affect the size nor the number of the 
lipid droplets represented by the green dots in Nile Red stained cells and had no observable effect on cell number and 
cellular shape. These observations suggest that the alteration of cell morphology and charged lipid content of the cell by 
41 at concentrations (≥ 33 µM) that are higher than those required to markedly inhibit HCV replication (EC50: 2.5 µM). 
All of these findings led us to conclude that compound 41 can be a useful tool to understand the biology of HCV 
infection. Alternatively it will be a useful prototype for the development of novel HCV therapeutics.  
With respect to the mechanism of action of 41 it is intriguing to speculate what structural features (long 
polymethylene linker and two phenolic moieties at the ends of the molecule) might contribute to its inhibitory action. As 
pointed out by several studies most of the bioactivities showed by the natural green tea catechins and synthetic alkyl 
gallates have been attributed to their antioxidant, free radical scavenging and metal chelating properties (iron, manganese, 
vanadium, copper, aluminium, calcium, etc…) [7c]..Another important aspect of these molecules that has special 
significance for their bioactivity is their amphipatic character. This property is due to the presence in their structures of 
hydrophobic aromatic rings and hydrophilic hydroxyls and allow them to stablish interactions with biologically relevant 
molecules such as proteins and polysaccharides [7c-k]. 
Taking into account the above general considerations we might speculate that the compound 41 might inhibit various 
stages in the HCV life cycle by targeting key non-structural HCV proteins such as NS3/4A protease, NS5B RNA-
dependent RNA polymerase and NS5A. In addition it might inhibit the HCV/host cell fusion process by targeting 
structural proteins on the HCV surface. Moreover the antioxidant properties of the phenolic rings present in 41 can affect 
host cell factors that are of importance in the replication of HCV.  
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Fig 2. Huh 9-13 cells were treated with different concentrations of derivative 41 (Panel A. 100 µM, B. 33 µM, C. 11 µM, D. 4 
µM, E. 1 µM) or mock treated (Panel F) and stained with Nile Red. Boxes highlight cells that are magnified in the insert of each 
panel. Nile Red stains both neutral lipids (green color) and phospholipids (red color). 
 
 
3. Conclusions 
 
We have synthesized different series of phenolic acid derivatives in which gallic acid (3,4,5-trihydroxybenzoic acid) 
and its isomer 2,3,4-trihydroxybenzoic acid, together with other mono- and dihydroxybenzoyl residues have been used as 
phenolic substituents and linear polyamines or polyalcohols as scaffolds. The compounds showed preferential activity 
against HIV and HCV. 
In general, the presence of free phenolic OHs is of crucial importance for the antiviral activity since the compounds 
with the phenolic OHs protected as OMe or OBn were, as a rule, inactive against HIV and HCV. 
With respect to the anti-HIV activity it was shown that tripodal compounds, with three phenolic moieties, showed 
higher activities than linear compounds with only one or two. 
With respect to the anti-hepatitis C virus activity, the most notable finding was the selective anti-hepatitis C virus 
activity shown by compounds 41 and 52 containing a 12-polymethylene chain and two 2,3 di- or 2,3,4 tri-hydroxybenzoyl 
groups located at the ends of the molecule. At least two contiguous hydroxyl groups on the aromatic ring seem to be 
important for activity since the compounds with only one OH on the aromatic ring were inactive.  
Interestingly, compounds bearing 2,3,4-trihydroxy benzoyl moieties were more active against both HIV and HCV 
than compounds substituted with galloyl groups. This observation led us to conclude that the 2,3,4-trihydroxyphenyl 
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moiety provides better antiviral activities than the gallic acid moiety. This moiety might serve for the further rational 
exploration of compounds with anti-HCV/HIV properties.  
Further studies are needed to develop derivatives with improved antiviral activity and to determine how these 
compounds inhibit HCV. 
 
4. Materials and methods  
Synthesis 
Microwave assisted conditions for the synthesis of alkyl gallates 2-7  
 A microwave vial was loaded with gallic acid 1 (0.3 mmol, 50 mg), the corresponding alcohol (0.9 mmol), and 
concentrated H2SO4 (0.07 mL). The reaction vessel was sealed and irradiated in a microwave reactor at 100 ºC for 50 
minutes. After cooling, volatiles were evaporated to dryness and the residue was dissolved in ethyl acetate (30 mL) and 
washed successively with saturated solutions of NaHCO3 (3 x 20 mL) and NaCl (1 x 20 mL). The organic layer was dried 
over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was then purified by column 
chromatography using hexane/EtOAc, (3:7) as the eluent. Melting points and characterization of compounds 2-7 were 
consistent with those found in the literature [25d]. In our case, the following yields were obtained: 2 (70%), 3 (97%), 4 
(83%), 5 (98%), 6 (96%), 7 (82%).   
 
Tetramethylene-1,4-diyl-bis-(3,4,5-trihydroxybenzoate) (8) 
Gallic acid 1 (3.3 mmol, 566 mg), 1,4-butanediol (1.1 mmol, 100 mg) and a catalytic amount of p-toluensulfonic acid 
were dissolved in dioxane (5 mL) in a distillation system. The mixture was heated at 160 ºC distilling the solvent which is 
continuously refilled until the reaction was completed. The reaction mixture was allowed to reach room temperature and 
then was cooled by a water-ice bath to give a precipitate that was filtered and washed with gently quantities of diethyl 
ether to give 305 mg (70%) of 8 as a white solid; m.p. 221-222 ºC.1H-NMR [(CD3)2CO, 300 MHz] δ 1.89 (m, 4H, CH2), 
4.30 (m, 4H, OCH2), 7.14 (s, 4H, ArH), 8.07 (s, 2H, OH), 8.27 (s, 4H, OH). 
13C-NMR [(CD3)2CO, 75 MHz] δ: 27.2 (CH2), 
65.7 (CH2), 110.6 (CH), 122.6 (C), 139.7 (C), 147.0 (C), 168.0 (CO). MS (ES+): m/z 395.3 (M+H)
+. Anal. C18H18O10 (C, 
H, N, O). 
 
Hexamethylene-1,6-diyl-bis-(3,4,5-trihydroxybenzoate) (9) 
Characterization of this compound in the literature was incomplete and NMR was registered in CDCl3
 [22b] and DMSO 
[22a]. Missing data (melting point) and NMR in acetone were now included.    
In a procedure analogous to that described for compound 8, gallic acid 1 (3.0 mmol, 510 mg) and 1,6-hexanediol (1.0 
mmol, 118 mg) afforded 83 mg (28%) of 9 as a white solid; m.p. 212-215 ºC. 1H-NMR [(CD3)2CO, 300 MHz] δ 1.50 (m, 
4H, CH2), 1.74 (m, 4H, CH2), 4.23 (t, J = 6.5 Hz, 4H, OCH2), 7.14 (s, 4H, ArH), 8.22 (bs, OH). MS (ES+): m/z 423 
(M+H)+. Anal. C20H22O10 (C, H, N, O). 
 
Octamethylene-1,8-diyl-bis-(3,4,5-trihydroxybenzoate) (10) 
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Characterization of this compound in the literature was incomplete and NMR was registered in CDCl3
 [22b] and DMSO 
[22a]. Missing data (melting point) and NMR in acetone were now included.    
In a procedure analogous to that described for compound 8, gallic acid 1 (3.0 mmol, 510 mg) and 1,8-octanediol (1.0 
mmol, 146 mg) afforded 221 mg (50%) of 10 as a white solid; m.p. 98-101 ºC. 1H-NMR [(CD3)2CO, 300 MHz] δ 1.50 (m, 
8H, CH2), 1.74 (m, 4H, CH2), 4.21 (t, J = 6.5 Hz, 4H, OCH2), 7.12 (s, 4H, ArH), 8.22 (bs, OH). MS (ES+): m/z 451 
(M+H)+. Anal. C22H26O10 (C, H, N, O). 
 
Dodecamethylene-1,12-diyl-bis-(3,4,5-trihydroxybenzoate) (11)  
Characterization of this compound in the literature was incomplete and NMR was registered in CDCl3
 [22b] and DMSO 
[22a]. Missing data (melting point) and NMR in acetone were now included.    
 In a procedure analogous to that described for compound 8, gallic acid 1 (3.0 mmol, 510 mg), and 1,12-dodecanediol (1.0 
mmol, 202.3 mg) afforded 264 mg (52%) of 11 as a white solid; m.p. 190-192ºC. 1H-NMR [(CD3)2CO, 300 MHz] δ 1.40 
(m, 16H, CH2), 1.74 (m, 4H, CH2), 4.21 (t, J = 6.5 Hz, 4H, OCH2), 7.12 (s, 4H, ArH), 8.21 (bs, OH). MS (ES+): m/z 507 
(M+H)+, 529 (M+Na)+. Anal. C26H34O10 (C, H, N, O). 
 
General procedure for the synthesis of alkyl amides 18-22, 24, 26 and 30.  
3,4,5-Trimethoxybenzoyl chloride 12 (3 eq) and potassium carbonate (3 eq) were dissolved in a mixture of ethyl 
acetate/water (1:1) and treated with the corresponding amine  (1 eqv). The resulting biphasic solution was stirred overnight 
and a white precipitate appeared. The solid (OMe protected derivative) was filtered and the filtrate was dried and 
subsequently dissolved in dry dichloromethane. The resulting solution was cooled by a water-ice bath (0-5ºC) and treated, 
under argon atmosphere, with boron tribromide (1.5 eq for each OMe group). The reaction was left to reach room 
temperature and stirred overnight. The precipitate that appeared was filtered and washed repeatedly with gently quantities 
of cold dichloromethane and ether to give the corresponding unprotected derivative as a white solid. Eventually some 
products had to be purified by reversed phase SPE cartridges using water/methanol (20:1 1:1) as the eluent. 
. 
N,N’-Tetramethylenebis(3,4,5-trihydroxybenzamide) (18)  
1,4-Tetramethylenediamine (75 mg, 0.88 mmol), potassium carbonate (364.87 mg, 2.64 mmol) and 3,4,5-
trimethoxybenzoyl chloride (12) (609 mg, 2.64 mmol) reacted according to the general procedure to give 380 mg (91%) of 
the OMe protected derivative 13 as a white solid; m.p. 243-244 ºC.1H-NMR [(CD3)2SO, 300 MHz] δ 1.55 (m, 4H, CH2), 
3.67 (m, 4H, CH2NH), 3.80 (s, 18H, OCH3), 7.1 (s, 4H, ArH), 8.42 (t, J = 5.5 Hz, 2H, NH). MS (ES+): m/z 477.0 (M+H)
+, 
499 (M+Na)+. Anal. C24H32N2O8 (C, H, N, O). 
Compound 13 (200 mg, 0.21 mmol) was treated with boron tribromide (0.12 mL) obtaining 62.3 mg (76%) of 18 as a 
white solid; m.p. 238-240 ºC.1H-NMR [(CD3)2SO, 300 MHz] δ 1.46 (bs, 4H, CH2), 3.16 (bs, 4H, CH2NH), 6.80 (s, 4H, 
ArH), 8.05 (wide s, 2H, NH); 8.83 (bs, 6H, OH). MS (ES+): m/z 393 (M+H)+. Anal. C18H20N2O8 (C, H, N, O). 
 
N,N’-Hexamethylenebis(3,4,5-trihydroxybenzamide) (19)  
 19 
 
 
 
 
 
1,6-Hexamethylenediamine (75 mg, 0.64 mmol), potassium carbonate (266.74 mg, 1,93 mmol)  and 3,4,5-
trimethoxybenzoyl chloride (12) (445 mg, 1.93 mmol) reacted according to the general procedure to give 314 mg (98%) of 
the OMe protected derivative 14 as a white solid; m.p. 219-221 ºC. 1H-NMR (CDCl3, 300 MHz) δ 1.45 (m, 4H, CH2), 1.64 
(m, 4H, CH2), 3.45 (c, J = 6.7 Hz, J = 6.2 Hz, 4H, CH2NH), 3.87 (s, 6H, OCH3), 3.90 (s, 12H, OCH3), 6.13 (t, J = 5.5 Hz, 
2H, NH), 6.99 (s, 4H, ArH). MS (ES+): m/z 505.3 (M+H)+. Anal. C26H36N2O8 (C, H, N, O). 
Compound 14 (200 mg, 0.40 mmol) was treated with boron tribromide (0.28 mL) obtaining 45.2 mg (51%) of 19 as a 
white solid. Melting point and spectroscopic characterization of compound 19 were consistent with those found in the 
literature [38]. 
 
N,N’-Octamethylenebis(3,4,5-trihydroxybenzamide) (20)  
1,8-Octamethylenediamine (100 mg, 1.13 mmol), potassium carbonate (468.5 mg, 3.39 mmol)  and 3,4,5-
trimethoxybenzoyl chloride (12) (780 mg, 3.39 mmol) reacted according to the general procedure to obtain 464 mg (77%) 
of the OMe protected derivative 15 as a white solid; m.p. 201-202 ºC. 1H-NMR (CDCl3, 300 MHz) δ 1.37 (m, 8H, CH2), 
1.63 (m, 4H, CH2), 3.43 (c, J = 6.9 Hz, J = 6.5 Hz, 4H, CH2NH), 3.87 (s, 18H, OCH3), 6.43 (t, J = 5.1 Hz, 2H, NH), 7.06 
(s, 4H, ArH). MS (ES+): m/z 533 (M+H)+. Anal. C28H40N2O8 (C, H, N, O).
 
Compound 15 (77 mg, 0.14 mmol) was treated with boron tribromide (0.08 mL) obtaining 54.3 mg (84%) of 20 as a 
white solid; m.p.155-157 ºC. 1H-NMR (CD3OD, 300 MHz) δ 1.38 (bs, 8H, CH2), 1.58 (m, 4H, CH2), 3.34 (m, 4H, 
CH2NH), 6.82 (s, 4H, HAr), MS (ES+): m/z 449 (M+H)
+. Anal. C22H28N2O8 (C, H, N, O). 
 
N,N’-Decamethylenebis(3,4,5-trihydroxybenzamide) (21)  
1,10-Decamethylenediamine (100 mg, 0.58 mmol), potassium carbonate (240.5 mg, 1.74 mmol) and 3,4,5-
trimethoxybenzoyl chloride (402 mg, 1.74 mmol) reacted according to the general procedure to obtain 179 mg (65%) of 
the OMe protected derivative 16 as an amorphous white solid; 1H-NMR [CDCl3, 300 MHz] δ 1.29 (m, 12H, CH2), 1.56 
(m, 4H, CH2), 3.30 (m, 4H, CH2NH), 3.83 (s, 18H, OCH3), 7.17 (s, 4H, ArH), 8.03 (bs, 2H, NH). MS (ES+): m/z 561 
(M+H)+. Anal. C30H44N2O8 (C, H, N, O). 
Compound 16 (100 mg, 0.18 mmol) was treated with boron tribromide (0.102 mL) obtaining 60.1 mg (70 %) of 21 as 
a white solid; m.p. 126-128 ºC. 1H-NMR [CD3OD, 300 MHz] δ 1.24-1.35 (m, 12H, CH2), 1.49-1.62 (m, 4H, CH2), 3.22-
3.32 (m, 4H, CH2NH, overlaps with CD3OD), 6.83 (s, 2H, ArH). 
13C-NMR [CD3OD, 75 MHz] δ 28.55 (CH2), 30.08 
(CH2), 30.99 (CH2), 32.90 (CH2), 41.35 (CH2), 108.14 (ArC), 108.96 (ArCH), 126.71 (ArC), 146.88 (ArC), 173.57 (C=O). 
MS (ES+): m/z 477.5 (M+H)+. Anal. C24H32N2O8 (C, H, N, O). 
 
 
N,N’-Dodecamethylenebis(3,4,5-trihydroxybenzamide) (22)   
1,12-Dodecamethylenediamine (100 mg, 0.50 mmol), potassium carbonate (207.3 mg, 1.50 mmol) and 3,4,5-
trimethoxybenzoyl chloride (345 mg, 1.50 mmol) reacted according to the general procedure to obtain 206 mg (70%) of 
the OMe protected derivative 17 as an amorphous white solid; 1H-NMR [CDCl3, 300 MHz] δ 1.29 (m, 16H, CH2), 1.55 
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(m, 4H, CH2), 3.28 (m, 4H, CH2NH), 3.83 (s, 18H, OCH3), 7.18 (s, 4H, ArH), 8.00 (bs, 2H, NH). MS (ES+): m/z 589 
(M+H)+. Anal. C32H48N2O8 (C, H, N, O). 
Compound 17 (100 mg, 0.17 mmol) was treated with boron tribromide (0.097 mL) obtaining 62.5 mg (70 %) of 22 as 
a white solid. Characterization of this compound in the literature [22b] was incomplete and NMR was made in DMSO-d6. 
Missing data (melting point) and NMR in acetone were now included; m.p. 135-137 ºC. 1H-RMN [(CD3)2SO, 300 MHz] δ 
1.24 (m, 16H, CH2), 1.45 (m, 4H, CH2), 3.16 (m, 4H, CH2NH), 6.80 (s, 4H, ArH), 8.00 (t, J = 5.5 Hz, 2H, NH), 8.25 (bs, 
OH). MS (ES+): m/z 505 (M+H)+. Anal. C26H36N2O8 (C, H, N, O). 
 
 
N,N’,N’’-Tris-(3,4,5-trihydroxybenzoyl)diethylenetriamine (24)  
Diethylenetriamine (100 mg, 0.96 mmol), potassium carbonate (531 mg, 3.84 mmol) and 3,4,5-trimethoxybenzoyl 
chloride (12) (708 mg, 3.07 mmol) reacted according to the general procedure to give 241 mg (38%) of the OMe protected 
derivative 23 as a white solid; m.p. 96-99 ºC. 1H-NMR [(CD3)2CO, 300MHz] δ 3.21 (m, 8H, CH2NH), 3.57-3.81 (m, 27H, 
OCH3), 6.5 (bs, 2H, ArH), 7.20 (wide s, 4H, ArH), 8.21 (wide s, 2H, NH). MS (ES+): m/z 686 (M+H)
+. Anal. 
C34H43N3O12 (C, H, N, O). 
Compound 23 (548 mg, 0.8 mmol) was treated with boron tribromide (0.70 mL) obtaining 130.5 mg (30%) of 24 as an 
amorphous white solid. 1H-NMR [D2O, 300MHz] δ 3.16-3.54 (m, 8H, CH2NH), 6.01 (bs, 2H, NH), 6.52 (bs, 3H, ArH 
6.62 (bs, 3H, ArH). MS (ES+): m/z 560 (M+H)+. Anal. C25H25N3O12 (C, H, N, O). 
 
N,N’,N’’-Tris(3,4,5-trihydroxybenzoyl)spermidine (26)  
Spermidine (50 mg, 0.34 mmol), potassium carbonate (188 mg, 1.36 mmol) and 3,4,5-trimethoxybenzoyl chloride (12) 
(313 mg, 1.36 mmol) reacted according to the general procedure to give 96.3 mg (39%) of the OMe protected derivative 
25 as a white solid; m.p. 78-80 ºC.1H-NMR [(CD3)2CO, 300MHz] δ 1.52 (m, 4H, CH2), 1.73 (m, 2H, CH2-CH2-NH), 3.43 
(m, 8H, CH2NH), 3.82 (s, 9H, OCH3), 3.83 (s, 9H, OCH3), 3.84 (s, 9H, OCH3), 7.23 (bs, 6H, H-Ar). MS (ES+): m/z 728 
(M+H)+. Anal. C37H49N3O12 (C, H, N, O). 
Compound 25 (72.7 mg, 0.1 mmol) was treated with boron tribromide (0.085 mL) obtaining 56.7 mg (95%) of 26 as a 
white solid. 1H-NMR (CD3OD, 300MHz) δ 1.76 (m, 6H, CH2), 2.99 (m, 8H, CH2-NH), 6.41 (bs, 3H, ArH), 6.85 (wide s, 
3H, ArH). MS (ES+): m/z 602 (M+H)+. Anal. C28H31N3O12 (C, H, N, O). 
 
Tris[2-(3’,4’,5’-trihydroxybenzamido)ethyl]amine (28)  
Tris(2-aminoethyl)amine (50 mg, 0.34 mmol), potassium carbonate (188 mg, 1.36 mmol) and 3,4,5-trimethoxybenzoyl 
chloride (12) (313 mg, 1.36 mmol) reacted according to the general procedure to give 171.8 mg (72%) of the OMe 
protected derivative 27 as a white solid. Characterization of this compound in the literature was incomplete [29] and NMR 
was made in CDCl3. Missing data (melting point) and NMR in acetone were now included; m.p. 150-152 ºC.
 1H-NMR 
[(CD3)2CO, 300MHz] δ 2.77 (t, J = 5.6 Hz, 6H, CH2N), 3.52 (m, 6H, CH2NH), 3.72 (s, 9H, OCH3), 3.76 (s, 18H, OCH3), 
7.17 (s, 6H, ArH), 7.98 (t, J = 5.1 Hz, 3H, NH). MS (ES+): m/z 729 (M+H)+. Anal. C36H48N4O12 (C, H, N, O). 
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Compound 27 (107 mg, 0.15 mmol) was treated with boron tribromide (0.13 mL) obtaining 82 mg (93%) of 28 as a 
white solid. Melting point and spectroscopic characterization of compound 28 were consistent with those found in the 
literature [29]. 
 
 
N,N’,N’’,N’’’,N’’’’-Pentakis(3,4,5-trihydroxybenzoyl)tetraethylenepentamine (30) 
Tetraethylenepentamine (50 mg, 0.26 mmol) potassium carbonate (215.6 mg, 1.56 mmol) and 3,4,5-trimethoxybenzoyl 
chloride (12) (359 mg, 1.56 mmol) reacted according to the general procedure to give 153.3 mg (85%) of the OMe 
protected derivative 29 as a white solid; m.p. 102-105 ºC. 1H-NMR [(CD3)2CO, 300MHz] δ 3.4-3.9 (m, 61H, CH2, OCH3), 
6.33-7.09 (m, 10H, ArH). MS (ES+): m/z 1161 (M+H)+. Anal. C58H73N5O20 (C, H, N, O).
 
Compound 29 (105 mg, 0.09 mmol) was treated with boron tribromide (0.13 mL) obtaining 30 quantitatively as a 
white solid; m.p. 175-177 ºC. 1H-NMR (CD3OD, 300MHz) δ 3.21-3.76 (m, 16H, CH2), 7.02-7.33 (m, 10H, ArH). MS 
(ES+): m/z 950 (M+H)+. Anal. C43H43N5O20 (C, H, N, O). 
 
General Method for the synthesis of alkyl amides 37-41, 43 and 45  
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP) (1.1 mmol for each NH moiety) was 
added to a solution of 2,3,4-tribenzyloxybenzoic acid 31 (1.1 mmol for each NH moiety) in dry dichloromethane (20 mL). 
After 5 min, triethylamine (TEA) (1 mmol for each NH moiety) and the corresponding amine (1 mmol) were added. The 
mixture was stirred at room temperature overnight and then evaporated to dryness. The residue was dissolved in ethyl 
acetate (30 mL) and washed successively with saturated solutions of citric acid (3 x 20 mL), NaHCO3 (3 x 20 mL) and 
NaCl (1 x 20 mL). The residue was concentrated and purified by column chromatography using hexane/ethyl acetate (5:1).  
A solution of the corresponding OBn protected derivative in THF/MeOH (1:1) containing 30 wt% of Pd/C (10%) was 
hydrogenated at 30 ºC overnight under atmospheric pressure using a reaction balloon filled with hydrogen gas and a glass 
flask as the reaction vessel. The Pd/C was filtered through Whatman® filter paper 42 and the solvent was removed under 
reduced pressure to give the crude product which was then purified by triturating with diethyl ether or dichloromethane to 
afford the corresponding deprotected derivative.  
 
N,N’-Tetramethylenebis(2,3,4-hydroxybenzamide) (37)  
According to the general procedure 1,4-tetramethylenediamine (35.2 mg, 0.40 mmol) was treated with 2,3,4-
tribenzyloxybenzoic acid 31 (440 mg, 1.00 mmol) to give 373 mg (100%) of the OBn protected derivative 32 as a white 
solid; m.p. 145-147 ºC. 1H-NMR [CDCl3, 300 MHz] δ 1.18-1.25 (m, 4H, CH2), 3.15-3.20 (m, 4H, CH2NH), 5.07 (s, 4H, 
CH2Ph), 5.11 (s, 4H, CH2Ph), 5.17 (s, 4H, CH2Ph), 6.89 (d, 2H, J = 9.6 Hz, ArH), 7.30-7.50 (m, 30H, ArH), 7.92 (d, 2H, J 
= 9.6 Hz, ArH). Anal. C60H56N2O8 (C, H, N, O). 
Following the deprotection procedure, the OBn derivative 32 (100 mg, 0.107 mmol) gave a crude product which was 
then purified by triturating with diethyl ether to afford 19.1 mg (46%) of 37 as a pale yellow solid; m.p. 225-227 ºC. 1H-
NMR [CD3OD, 300 MHz] δ 1.60-1.78 (m, 4H, CH2), 3.35-3.50 (m, 4H, CH2NH), 6.34 (d, 2H, J = 9.2 Hz, ArH), 7.12 (d, 
2H, J = 9.2 Hz, ArH). 13C-NMR [CD3OD, 75 MHz] δ 26.57 (CH2), 38.56 (CH2), 106.37 (ArC), 107.47 (ArC), 117.63 
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(ArC), 132.56 (ArC), 149.21 (ArC), 150.22 (ArC), 170.47 (C=O). MS (ES+): m/z 393.3 (M+H)+. MS (ES+): m/z 393 
(M+H)+. Anal. C18H20N2O8 (C, H, N, O). 
 
N,N’-Hexamethylenebis(2,3,4-hydroxybenzamide) (38)  
According to the general procedure 1,6-hexamethylenediamine (23,3 mg, 0.20 mmol) was treated with 2,3,4-
tribenzyloxybenzoic acid 31 (220 mg, 0.50 mmol) to give 131.3 mg (69%) of the OBn protected derivative 33 as a white 
solid; m.p. 134-135 ºC. 1H-NMR [CDCl3, 300 MHz] δ 1.05-1.17 (m, 4H, CH2), 1.17-1.32 (m, 4H, CH2), 3.16-3.27 (m, 4H, 
CH2NH), 5.08 (s, 4H, CH2Ph), 5.13 (s, 4H, CH2Ph), 5.16 (s, 4H, CH2Ph), 6.88 (d, 2H, J = 9.3 Hz, ArH), 7.28-7.51 (m, 
30H, ArH), 7.92 (d, 2H, J = 9.3 Hz, ArH). 13C-NMR [CDCl3, 75 MHz] δ 26.99 (CH2), 29.49 (CH2), 39.95 (CH2), 71.46 
(CH2Ph), 76.06 (CH2Ph), 109.73 (ArCH), 120.12 (ArC), 127.99 (ArCH), 128.62 (ArCH), 128.82 (ArCH), 129.06 (ArCH), 
129.08 (ArCH), 129.16 (ArCH), 132.46 (ArC), 133.57 (ArC), 136.67 (ArC), 136.73 (ArC), 137.57 (ArC), 141.61 (ArC), 
152.07 (ArC), 156.05 (ArC), 165.15 (C=O). Anal. C62H60N2O8 (C, H, N, O).
 
Following the deprotection procedure, the OBn derivative 33 (121.66 mg, 0.126 mmol) gave a crude product which 
was then purified by triturating with diethyl ether to give 22 mg (42 %) of 38 as a pale yellow solid; m.p. 163-165 ºC. 1H-
NMR [CD3OD, 300 MHz] δ 1.40-1.49 (m, 4H, CH2), 1.56-1.69 (m, 4H, CH2), 3.30-3.40 (m, 4H, CH2NH, overlaps with 
CD3OD), 6.35 (d, 2H, J = 8.8 Hz, ArH), 7.13 (d, 2H, J = 8.8 Hz, ArH). 
13C-NMR [CD3OD, 75 MHz] δ 26.86 (CH2), 29.45 
(CH2), 39.45 (CH2), 106.82 (ArC), 107.95 (ArCH), 117.94 (ArCH), 133.02 (ArC), 149.52 (ArC), 150.48 (ArC), 170.74 
(C=O). MS (ES+): m/z 421.4 (M+H)+. Anal. C20H24N2O8 (C, H, N, O). 
 
N,N’-Octamethylenebis(2,3,4-hydroxybenzamide) (39)  
According to the general procedure 1,8-octamethylenediamine (28.8 mg, 0.20 mmol) was treated with 2,3,4-
tribenzyloxybenzoic acid 31 (220 mg, 0.50 mmol) to give 121.9 mg (62%) of the OBn protected derivative 34 as a white 
solid; m.p. 122-124 ºC. 1H-NMR [CDCl3, 300 MHz] δ 1.09-1.23 (m, 8H, CH2), 1.23-1.35 (m, 4H, CH2), 3.19-3.28 (m, 4H, 
CH2NH), 5.09 (s, 4H, CH2Ph), 5.12 (s, 4H, CH2Ph), 5.17 (s, 4H, CH2Ph), 6.89 (d, 2H, J = 9.1 Hz, ArH), 7.26-7.49 (m, 
30H, ArH), 7.86 (bs, 1H, NH), 7.93 (d, 2H, J = 9.1 Hz, ArH). 13C-NMR [CDCl3, 75 MHz] δ 27.56 (CH2), 29.59 (CH2), 
29.72 (CH2), 39.95 (CH2), 71.29 (CH2Ph), 76.23 (CH2Ph), 109.67 (ArCH), 120.35 (ArC), 127.31 (ArCH), 128.00 (ArCH), 
128.61 (ArCH), 128.81 (ArCH), 129.05 (ArCH), 129.09 (ArCH), 129.13 (ArCH), 136.67 (ArC), 136.81 (ArC), 137.55 
(ArC), 141.46 (ArC), 152.17 (ArC), 156.02 (ArC), 165.14 (C=O). Anal. C64H64N2O8 (C, H, N, O). 
Following the deprotection procedure, the OBn derivative 34 (112.2 mg, 0.113 mmol) gave a crude product which was 
then purified by triturating with dichloromethane to afford 25 mg (48 %) of 39 as a white solid; m.p. 179-181 ºC. 1H-NMR 
[CD3OD, 300 MHz] δ 1.36-1.44 (m, 8H, CH2), 1.55-1.67 (m, 4H, CH2), 3.27-3.36 (m, 4H, CH2NH, overlaps with 
CD3OD), 6.35 (d, 2H, J = 8.8 Hz, ArH), 7.12 (d, 2H, J = 8.8 Hz, ArH). 
13C-NMR [CD3OD, 75 MHz] δ 27.98 (CH2), 30.33 
(CH2), 30.50 (CH2), 40.36 (CH2), 107.79 (ArC), 108.98 (ArCH), 119.05 (ArCH), 133.57 (ArC), 150.71 (ArC), 151.54 
(ArC), 171.76 (C=O). MS (ES+): m/z 449.6 (M+H)+. Anal. C22H28N2O8 (C, H, N, O). 
 
 
 
N,N’-Decamethylenebis(2,3,4-hydroxybenzamide) (40)  
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According to the general procedure 1,10-diaminodecane (34.5 mg, 0.20 mmol) was treated with 2,3,4-tribenzyloxybenzoic 
acid (220 mg, 0.50 mmol) to give 97.4 mg (51%) of the OBn protected derivative 35 as a white solid; m.p. 110-112 ºC. 1H-
NMR [CDCl3, 300 MHz] δ 1.17-1.23 (m, 12H, CH2), 1.25-1.35 (m, 4H, CH2), 3.21-3.29 (m, 4H, CH2NH), 5.08 (s, 4H, 
CH2Ph), 5.13 (s, 4H, CH2Ph), 5.17 (s, 4H, CH2Ph), 6.89 (d, 2H, J = 9.2 Hz, ArH), 7.28-7.48 (m, 30H, ArH), 7.92 (d, 2H, J 
= 9.2 Hz, ArH). 13C-NMR [CDCl3, 75 MHz] δ 27.35 (CH2), 29.72 (CH2), 29.89 (CH2), 39.82 (CH2), 71.30 (CH2Ph), 76.01 
(CH2Ph), 109.60 (ArCH), 120.18 (ArC), 127.30 (ArCH), 127.99 (ArCH), 128.61 (ArCH), 128.81 (ArCH), 129.11 (ArCH), 
136.68 (ArC), 136.75 (ArC), 137.51 (ArC), 141.75 (ArC), 152.22 (ArC), 156.03 (ArC), 165.17 (C=O. Anal. C66H68N2O8 
(C, H, N, O). 
Following the deprotection procedure, the OBn derivative 35 (90 mg, 0.088 mmol) gave a crude product which was 
then purified by triturating with dichloromethane to afford 25.3 mg (61 %) of 40 as a white solid; m.p. 177-179 ºC. 1H-
NMR [CD3OD, 300 MHz] δ 1.28-1.39 (m, 12H, CH2), 1.52-1.64 (m, 4H, CH2), 3.27-3.39 (m, 4H, CH2NH, overlaps with 
CD3OD), 6.35 (d, 2H, J = 9.1 Hz, ArH), 7.12 (d, 2H, J = 9.1 Hz, ArH). 
13C-NMR [CD3OD, 75 MHz] δ 28.02 (CH2), 30.35 
(CH2), 30.50 (CH2), 30.54 (CH2), 40.36 (CH2), 107.77 (ArC), 108.96 (ArCH), 119.03 (ArCH), 133.96 (ArC), 150.57 
(ArC), 151.56 (ArC), 171.74 (C=O). MS (ES+): m/z 477.5 (M+H)+. Anal. C24H32N2O8 (C, H, N, O). 
 
N,N’-Dodecamethylenebis(2,3,4-hydroxybenzamide) (41) 
According to the general procedure 1,12-dodecamethylendiamine (80.14 mg, 0.40 mmol) was treated with 2,3,4-
tribenzyloxybenzoic acid (440 mg, 1 mmol) to give 417 mg (100%) of the OBn protected derivative 36 as a white solid; 
m.p. 92-94 ºC. 1H-NMR [CDCl3, 300 MHz] δ 0.90-1.00 (m, 4H, CH2), 1.17-1.40 (m, 16H, CH2), 3.20-3.40 (m, 4H, CH2-
NH), 5.07 (s, 4H, CH2Ph), 5.14 (s, 4H, CH2Ph), 5.19 (s, 4H, CH2Ph), 6.80-7.00 (m, 2H, ArH), 7.28-7.51 (m, 28H, ArH), 
7.80-8.00 (m, 4H, ArH). Anal. C68H72N2O8 (C, H, N, O).
 
Following the deprotection procedure, the OBn derivative 36 (106 mg, 0.102 mmol) gave a crude product which was 
then purified by triturating with dichloromethane to afford 24 mg (47 %) of 41 as a white solid; m.p. 151-153 ºC. 1H-NMR 
[CD3OD, 500 MHz] δ 1.20-1.47 (m, 16H, CH2), 1.52-1.58 (m, 4H, CH2), 3.30-3.40 (m, 4H, CH2NH), 6.34 (d, 2H, J = 8.8 
Hz, ArH), 7.12 (d, 2H, J = 8.8 Hz, ArH). 13C-NMR [CD3OD, 75 MHz] δ 28.54 (CH2), 30.89 (CH2), 31.01 (CH2), 31.12 
(CH2), 31.14 (CH2), 40.89 (CH2), 108.27 (ArC), 109.47 (ArC), 119.54 (ArC), 134.49 (ArC), 151.08 (ArC), 152.09 (ArC), 
172.25 (C=O). MS (ES+): m/z 505.3 (M+H)+. Anal. C26H36N2O8 (C, H, N, O). 
 
N,N’,N’’-Tris(2,3,4-trihydroxybenzoyl)spermidine (43)  
According to the general procedure spermidine (50 mg, 0.34 mmol) was treated with 2,3,4-tribenzyloxybenzoic acid 31 
(500 mg, 1.13 mmol) to give 240 mg (75%) of the OBn protected derivative 42 as a white solid; m.p. 68-70 ºC. 1H-NMR 
[CDCl3, 300 MHz] δ 1.00-1.20 (m, 1H, CH2), 1.30-1.42 (m, 2H, CH2), 1.43-1.54 (m, 2H, CH2), 1.60-1.76 (m, 1H, CH2), 
2.80-3.00 (m, 1H, CH2), 3.02-3.20 (m, 4H, CH2), 3.20-3.40 (m, 2H, CH2), 3.60-3.80 (m, 1H, CH2), 4.96-5.30 (m, 18H, 
CH2Ph), 6.70-6.96 (m, 5H, ArH), 7.20-7.60 (m, 42H, ArH), 7.70-8.10 (m, 4H, ArH). Anal. C91H85N3O12 (C, H, N, O). 
Following the deprotection procedure, the OBn derivative 42 (128.7 mg, 0.09 mmol) gave a crude product which was 
then purified by triturating with diethyl ether to afford 23 mg (42 %) of 43 as a white solid; m.p. 185-187 ºC. 1H-NMR 
[CD3OD, 300MHz] δ 1.30-1.60 (m, 4H, CH2), 1.70-1.80 (m, 2H, CH2), 3.25-3.62 (m, 8H, CH2NH), 6.22-6.31 (m, 3H, 
ArH), 6.43 (d, 1H, J = 8.3 Hz, ArH), 7.01 (d, 2H, J = 8.3 Hz, ArH). 13C-NMR [CD3OD, 75 MHz] δ 26.30 (CH2), 28.10 
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(CH2), 36.03 (CH2), 38.37 (CH2), 48.20 (CH2), 54.62 (CH2), 106.39 (ArC), 106.51 (ArC), 106.82 (ArC), 107.34 (ArC), 
107.47 (ArC), 115.67 (ArC), 117.55 (ArC), 117.60 (ArC), 117.64 (ArC), 132.54 (ArC), 132.56 (ArC), 132.94 (ArC), 
143.02 (ArC), 147.04 (ArC), 149.22 (ArC), 149.26 (ArC), 150.20 (ArC), 150.24 (ArC), 170.41 (C=O), 170.43 (C=O), 
171.81 (C=O). MS (ES+): m/z 602.2 (M+H)+. Anal. C28H31N3O12 (C, H, N, O). 
 
Tris[2-(2’,3’,4’-trihydroxybenzamide)ethyl]amine (45) 
According to the general procedure tris(2-aminoethyl)amine (0.052 mL, 0.34 mmol) was treated with 2,3,4-
tribenzyloxybenzoic acid 31 (494 mg, 1.12 mmol) to give 478 mg (100%) of the OBn protected derivative 44 as a 
colourless oil. 1H-NMR (CDCl3, 300MHz) δ 2.65 (dd, J = 0.48 Hz, J = 9.31 Hz, 12 H, CH2NH), 5.03 (s, 6H, CH2O), 5.10 
(s, 12H, CH2O), 7.36 (m, 51H, ArH). MS (ES+): m/z 1413 (M+H)
+. Anal. CxH30N4O12 (C, H, N, O). 
Following the deprotection procedure, the OBn derivative 44 (220 mg, 0.15 mmol) gave a crude product which was 
then purified by triturating with diethyl ether to afford 32 mg (35%) of 45 as a white solid. Characterization of this 
compound in the literature was incomplete [29c] and NMR was made in D2O.. Missing data (melting point) and NMR in 
methanol were now included; m.p. 154-156 ºC.1H-NMR (CD3OD, 300MHz) δ 2.83 (t, J = 6.20 Hz, 6H, CH2NH), 3.49 (t, J 
= 6.12 Hz, 6H, CH2NH), 6.26 (d, J = 8.80 Hz, 3H, ArH), 7.03 (d, J = 8.81 Hz, 3H, ArH). MS (ES+): m/z 603 (M+H)
+. 
Anal. C27H30N4O12 (C, H, N, O). 
 
General Method for the synthesis of alkyl amides 50-52 and 57-59 
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP) (2.2 mmol) was added to a solution of 
2,3-dimethoxybenzoic acid 46 (2.2 mmol) or 2-benzyloxysalicylic acid 53 (2.2 mmol) in dry dichloromethane (20 mL). 
After 5 min, triethylamine (TEA) (2 mmol) and the corresponding diamine (1 mmol) were added. The mixture was stirred 
at room temperature overnight and then evaporated to dryness. The residue was dissolved in ethyl acetate (30 mL) and 
washed successively with saturated solutions of citric acid (3 x 20 mL), NaHCO3 (3 x 20 mL) and NaCl (1 x 20 mL). The 
residue was concentrated and purified by preparative centrifugal circular thin-layer chromatography (CCTLC) using 
dichloromethane/methanol (9:1 1:1) as the eluent. 
The protected OMe derivatives 47-49 were deprotected using boron tribromide as was previously described to afford 
the deprotected derivatives 50-52. Melting points and characterization of these compounds were consistent with those 
found in the literature [31]. In our case the following total yields were obtained: 50 (81%), 51 (99%) and 52 (50%).  
Deprotection of the benzyl groups of 54-56 by catalytic hydrogenation in the presence of 10% Pd/C as was previously 
described afforded the corresponding phenol deprotected derivatives 57 (74%), 58 (99%) and 59 (50%). Melting points 
and characterization of these compounds were consistent with those found in the literature [31a, 39]. 
 
N,N’-4,7,10-Trioxa-1,13-tridecanebis(2,3,4-hydroxybenzamide) (61)  
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP) (0.37 mmol) was added to a solution of 
2,3,4-tribenzyloxybenzoic acid 31 (163.7 mg, 0.37 mmol)  in dry dichloromethane (5 mL). After 5 min, triethylamine 
(TEA) (0.37 mmol) and 4,7,10-trioxa-1,13-tridecanediamine (35.24 mg, 0.16 mmol) were added. The mixture was stirred 
at room temperature overnight and then evaporated to dryness. The residue was dissolved in ethyl acetate (20 mL) and 
washed successively with saturated solutions of citric acid (3 x 20 mL), NaHCO3 (3 x 20 mL) and NaCl (1 x 20 mL). The 
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residue was concentrated and purified by preparative centrifugal circular thin-layer chromatography (CCTLC) using 
hexane/ethyl acetate (1:1) as eluent to give 96.5 mg (57%) of the OBn protected derivative 60 as a colourless oil. 1H-NMR 
[CDCl3, 300 MHz] δ 1.50-1.60 (m, 4H, CH2), 3.35 (q, 4H, J = 6.4 Hz, CH2O), 3.35 (t, 4H, J = 5.8 Hz, CH2NH), 3.43-3.49 
(m, 4H, CH2O), 3.51-3.56 (m, 4H, CH2O), 4.97 (s, 4H, CH2Ph), 5.02 (s, 8H, CH2Ph), 6.74 (d, 2H, J = 8.7 Hz,  ArH), 7.19-
7.38 (m, 30H, ArH), 7.77 (d, 2H, J = 8.7 Hz, ArH), 7.92 (t, 2H, J = 5.5 Hz, NH).13C-NMR [CDCl3, 75 MHz] δ 29.70 
(CH2), 36.80 (CH2), 69.12 (CH2), 70.09 (CH2), 70.28 (CH2), 71.27 (CH2Ph), 76.10 (CH2Ph), 109.47 (ArCH), 119.82 
(ArCH), 128.00 (ArCH), 128.81 (ArCH), 129.03 (ArCH), 129.18 (ArCH), 136.64 (ArC), 137.60 (ArC), 141.34 (ArC), 
152.16 (ArC), 156.17 (ArC), 165.55 (C=O). Anal. C66H68N2O11 (C, H, N, O). 
Following the deprotection procedure, the OBn derivative 60 (89.6 mg, 0.084 mmol) gave a crude product which 
was coevaporated with diethyl ether to give 40 mg (73%) of 61 as a brownish oil. 1H-NMR [CD3OD, 300 MHz] δ  1.74 (q, 
4H, J = 6.4 Hz, CH2), 3.17-3.61 (m, 16H, CH2O, CH2NH), 6.25 (d, 2H, J = 8.8 Hz,  ArH), 7.00 (d, 2H, J = 8.8 Hz, ArH). 
13C-NMR [CD3OD, 75 MHz] δ 30.61 (CH2), 38.25 (CH2), 70.72 (CH2), 71.41 (CH2), 71.66 (CH2), 108.25 (ArC), 109.95 
(ArCH), 119.47 (ArCH), 134.03 (ArC), 150.96 (ArC), 151.93 (ArC), 172.06 (C=O). MS (ES+): m/z 525.5 (M+H)+. Anal. 
C24H32N2O11 (C, H, N, O). 
 
N,N’-Dodecamethylenbis(2,3,4-trimethoxybenzamide) (63)  
In a procedure analogous to that described for compound 60, benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (pyBOP) (0.5 mmol) and 2,3,4-trimethoxybenzoic acid 62 (106.1 mg, 0.5 mmol) in dry 
dichloromethane (5 mL) was treated with triethylamine (TEA) (0.5 mmol) and 1,12-dodecamethylendiamine (34.46 mg, 
0.20 mmol) to obtain 85.2 mg (72%) of 63 as a white solid; m.p. 62-64 ºC. 1H-NMR [CDCl3, 300 MHz] δ 1.18-1.41 (m, 
16H, CH2), 1.50-1.62 (m, 4H, CH2), 3.40 (q, 4H, J = 6.6 Hz, CH2NH), 3.82 (s, 6H, CH3), 3.85 (s, 6H, CH3), 3.91 (s, 6H, 
CH3), 6.72 (d, 2H, J = 9.5 Hz, ArH), 7.84 (d, 2H, J = 9.5 Hz, ArH), 7.87-7.93 (m, 2H, NH). 
13C-NMR [CDCl3, 75 MHz] δ 
27.31 (CH2), 29.52 (CH2), 29.75 (CH2), 29.83 (CH2), 39.79 (CH2), 56.21 (CH3), 61.13 (CH3), 107.73 (ArC), 119.35 (ArC), 
126.79 (ArC), 141.88 (ArC), 152.48 (ArC), 156.40 (ArC), 164.97 (C=O). Anal. C50H84N2O8 (C, H, N, O). 
 
Supporting information 
General chemistry and biological procedures as well as copies of representative 1H and 13CNMR spectra are included. 
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